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background: While mortality benefit of spironolactone in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) has 
been well-described, there is no clinical study demonstrating this effect in diabetics versus non-diabetics.
Methods: From 2002 to 2012, all consecutive patients ≥18 years with systolic HF (LVEF ≤35%) on standard medical therapy with a beta-blocker 
and ACE inhibitor or angiotensin-receptor blocker from 3 hospitals of Montefiore Medical Center were included and divided into diabetics and non-
diabetics. Each group was stratified by whether or not they were on spironolactone after diagnosis of HF. Endpoint was 2-year all-cause mortality.
results: Of 3,160 patients included (age 63 ± 15; 65% male), 1,650 were diabetic and 1,510 were non-diabetic. During 2-year follow-up, 536 
(48%) diabetics and 498 (49%) non-diabetics were on spironolactone. While in diabetics, spironolactone significantly reduced mortality compared 
to no spironolactone (14.8 vs 20%, RR 0.70 [95% CI 0.54-0.91]; p=0.008), there was no significant mortality reduction in non-diabetics (14.1 vs 
15.4%, RR 0.89 [95% CI 0.67-1.19]; p=0.451).
conclusion: In this multicenter study, spironolactone showed a mortality benefit in diabetics with HF, while there was no benefit in non-diabetics. 
These observations may be a result of anti-inflammatory effect of spironolactone or blockade of aldosterone-induced vascular insulin resistance role 
in vascular dysfunction seen especially in diabetes.
 
